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ORIGINAL ARTICLE
Aggressive ® bromatosis: evidence for a stable phase
GILLIAN MITCHELL, J. MEIRION THOMAS & CLIVE L. HARMER
Sarcoma Unit, Royal Marsden Hospital NHS Trust, London SW3 6JJ, UK
Abstract
Purpose. Aggressive ® bromatosis (AF) is an uncommon locally in® ltrating benign disease of soft tissue for which
treatment comprises complete surgical resection. Radiotherapy can be given postoperatively if the margin is incompletely
resected. If the tumour is inoperable radiotherapy provides an alternative treatment. Hormone therapy and cytotoxic
chemotherapy have also been used for unresectable or recurrent disease. All treatment modalities carry an associated
morbidity. We believe that the natural history of aggressive ® bromatosis may include a period of stable disease without
progression, during which time, treatment is not always necessary.
Patients and methods. We present a retrospective review of 42 patients referred to the Royal Marsden Hospital between
1988 and 1995 with aggressive ® bromatosis. Evidence of periods of stable disease and the relationship to delivered
treatment was obtained from the case notes, including the natural history prior to referral to our institution. Stable disease
was de® ned as a period of no objective progression for 6 months or longer.
Results. Seventeen patients could be assessed for stable disease and all (100%) experienced at least one episode of stable
disease, eight of whom whilst receiving hormonal or cytotoxic therapy. Of the 23 patients who could not be assessed for
stable disease, as they underwent surgery at presentation or recurrence of disease, only 2 had persisting disease at last
follow-up. Both of these patients had had positive surgical resection margins.
Discussion. This study demonstrates the variable natural history of AF, which can include a substantial period of stable
disease in a signi® cant number of patients. A less aggressive approach to the management of AF may therefore be
appropriate, particularly if a subgroup of patients who are likely to experience a period of stable disease can be identi® ed.
Key words: aggressive ® bromatosis, stable growth phase.
Introduction
Aggressive ® bromatosis is an uncommon benign soft
tissue neoplasm. Because of its tendency for recur-
rence, it is usually categorised together with malig-
nant soft tissue neoplasms of which it constitutes
less than 4%.
1 The reported annual incidence is
0.2± 0.5/100 000 population.
2 It occurs more com-
monly in women and in the younger population.
Aetiology is unknown but there are associations with
trauma (including surgery), pregnancy, and oestro-
gen exposure. There is a rare familial type, which
may be part of Gardner’s syndrome.
Fibromatosis was ® rst described more than 150
years ago by McFarlane.
2 Because of its rarity, most
published series describe only small numbers of
patients and there remains uncertainty as to the
most appropriate method of treatment. Current
approaches include surgery, radiotherapy, chemo-
therapy, endocrine therapy and observation, either
alone or in combination.
Assessment of response to therapy has tradition-
ally included only local control and recurrence rates.
However, there is the impression in our institution
that there may be a plateau phase in its natural
history when there is no progression, i.e. a period of
stable disease. If this exists then there are serious
implications for management, particularly when
treatments can involve either extensive surgery or
potentially mutagenic treatments such as radiother-
apy, chemotherapy and endocrine therapy. Further-
more, if there is a plateau phase then it must be
taken into account when assessing response to treat-
ment. Growth arrest with any of these treatments
may be unrelated to that treatment and failure to
progress (stable state) cannot be considered an
objective response.
Materials and methods
A retrospective analysis was made of 42 evaluable
patients referred to one surgeon at the Royal Mars-
den Hospital (RMH), with a diagnosis of aggressive
® bromatosis between 1988 and 1995. Twenty-one
patients were referred with recurrent disease after
treatment elsewhere and 21 presented de novo. A
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Table 1. Tumour site in patients with or without stable disease (SD)
Site
Abdominal wall Intra-abdominal Pelvis Others
Patients with SD 1 1 3 14
Patients without SD 3 3 1 16
range of treatments was offered from observation
only, surgery alone, surgery and radiotherapy (30±
60 Gy in 15± 30 fractions given over 3± 6 weeks),
toremifene 40 mg daily, or chemotherapy with
methotrexate (50 mg weekly) plus vinblastine (10
mg weekly). A wide excision was the aim of surgery,
if practically possible. Wide excision is the removal
of all gross disease with a surrounding margin of
healthy tissue. Follow up ranged from 11 months to
8 years (median 3 years). Twelve patients were not
followed up, but the natural history of their disease
prior to referral is included in the analysis. Follow-
up data are available on 30 patients.
Stable disease was de® ned as a period of no
objective progression for 6 months or longer. Evi-
dence of stable disease was obtained from case
notes, either reported by patients in their initial
history or by documented reports during follow up
at RMH. Progressive disease was de® ned as an
increase in size or symptoms related to the tumour.
Complete response was resolution of all gross dis-
ease following therapy. Partial response was a
reduction in size of the tumour by 50% or greater in
all dimensions maintained for two consecutive
assessments at least 3 months apart. Residual dis-
ease was de® ned as microscopic, if all gross disease
was removed but margins were positive on
microscopy, or macroscopic, if gross disease
remained. The periods of progressive, stable or
regressing disease were then correlated with the type
of treatment administered.
Results
The case notes of 42 patients with aggressive
® bromatosis seen at RMH were retrospectively
analysed. Twenty nine patients were female and 13
male. The age range at the time of referral was
16± 75 years (median 34 years). Of the patients who
presented with recurrent disease, 2 were found to
have scar tissue only, 8 patients had developed their
® rst recurrence and 11 had undergone multiple
excisions with or without radiotherapy. Six patients
had 2 or more sites of disease. The anatomical sites
of involvement are shown in Table l.
Episodes of stable disease
Episodes of stable disease were seen in 17 patients
(40%). Fifteen patients had stable disease docu-
mented following referral to RMH, 4 of these also
had stable disease prior to RMH referral. Only two
patients had stable disease that was not observed at
RMH but had been documented by the referring
hospital. Spontaneous regression was seen in 2 addi-
tional patients. One patient with stable disease also
experienced spontaneous regression at one site and
experienced stable disease at another, separate, site.
Table 2 summarises these data. Twelve patients
were female and 7 male. The period of stable dis-
ease ranged from 6 months to 12 years (median 3
years). Nine of these patients had periods of stable
disease on no treatment. Eight patients had stable
disease while on treatment. Seven were being
treated with toremifene (20 mg daily). Three
patients were also treated with methotrexate plus
vinblastine and one patient with chemotherapy
alone.
Four of these patients continued to have stable
disease after completion of therapy from 21 to 36
months and 4 have continued to have stable disease
while continuing with therapy. Three patients
experienced a spontaneous regression.
No episode of stable disease
Twenty-three patients could not be assessed for
stable disease as they were treated by surgery. All
but two or these had recurrent disease at referral.
Twelve patients underwent surgery alone, 5 received
surgery and radiotherapy, 3 commenced toremifene
and one was started on chemotherapy. The latter 4
patients progressed on drug therapy and one of
these had a further resection and remains disease
free. Table 3 outlines outcome after surgery in
relation to the histological excision margin in
patients treated with surgery with or without radio-
therapy. Five patients had surgery followed by adju-
vant radiotherapy for positive histological margins.
Follow-up data are available on only two of these:
both remain free of disease 3 and 4 years post-
irradiation. The ® nal three patients were not treated
at RMH having been discharged after their initial
consultation.
In summary, of these 23 patients, only 2 still had
persisting disease at their last follow-up, despite the
presence of gross residual disease or positive resec-
tion margins in 10 (13 if unknown excision margins
are included). Both patients with persisting disease
had previously relapsed on more than one occasionStable phase in aggressive ® bromatosis 151
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Table 3. Disease outcome related to status of surgical margins in patients
treated by surgery with or without radiotherapy: x 5 no follow-up
Histological
Patient No. margins Disease status FU (months)
3 micro positive x x
5 gross disease recurrence 5
6 gross disease disease free 30
8 clear x x
9 clear disease free 1
10 not reported disease free 72
11 not reported disease free 35
12 clear disease free 66
13 clear disease free 11
14 gross disease disease free 11
15 clear disease free 23
16 micro positive disease free 25
17 micro positive disease free 38
18 micro positive disease free 50
19 micro positive x x
20 micro positive x x
21 micro positive x x
23 not reported disease free 26
and had gross residual disease following their most
recent resection.
Discussion
The ® bromatoses comprise a number of distinct
clinicopathological types: palmar and plantar
® bromatosis, penile ® bromatosis (Peyronie’s dis-
ease) and aggressive ® bromatosis (desmoid
tumour). The latter are divided into abdominal or
extra-abdominal sites. The abdominal tumours usu-
ally occur in the muscular aponeurotic structures of
the anterior abdominal wall, particularly in post-
partum women. Extra-abdominal tumours occur at
any site but are more usual around the shoulder
girdle, inguinal region and lower extremities.
Histologically the tumour consists of interlacing
bundles of spindle cells (® broblasts) with variable
amounts of collagen, which in® ltrate the surround-
ing structures. There can be vigorous cellularity at
the edge of the lesion in comparison to a relatively
poorly cellular core and this, together with the ten-
dency to in® ltrate and a high tendency to recurrence
post-excision, has led some authors to describe the
condition as low-grade ® brosarcoma.
3,4 Metastases
do not occur.
The importance of aggressive ® bromatosis is a
tendency to in® ltrate widely which has led most
practitioners to treat this tumour in a manner simi-
lar to a low-grade sarcoma, by performing a wide
excision. The risk of local recurrence after non-wide
resection is 8± 70%.
1,5,6,7 Multiple previous recur-
rences and residual disease predict for further recur-
rence. However, there are also reports of lack of
recurrence or progressive disease in cases that are
known to have had either gross residual disease or
microscopically positive margins at surgery.
3,8,9,10
This implies that the persistence of tumour cells
does not necessarily equate with progressive disease.
This has been con® rmed in our series.
Other modalities used in the management of this
disease include radiotherapy, hormone therapy and
chemotherapy. Assessment of response includes
recurrence rates or response rates (including partial
and complete response) and stable disease. In our
series 40% of patients had stable disease either with
or without treatment. Therefore it is important to
identify in reported series the type of response in
order to assess the possible bene® t of treatment.
Radiotherapy is frequently recommended in both
the primary and adjuvant setting. Radiotherapy
series have shown a local recurrence rate of 20±
46%.
4,5,7,9± 16 Some series indicate the proportion of
complete, partial and stable disease response to
treatment, which is summarised in Table 4,
although the majority describes complete response
or persisting disease only.
The reported use of toremifene and chemo-
therapy, in the management of this disease is lim-
ited.
17± 21 Reports describe small numbers of patients
and response rates are quoted as 65± 75%, but
include stable disease, partial and complete
response. In our series, 8 patients (67%) had stable
disease while using toremifene or chemotherapy, but
no patient had a partial or complete response.
It can be seen that there is a wide variation in the
natural history of aggressive ® bromatosis, ranging
from spontaneous remission to multiple recurrences
post-treatment, regardless of the modality of treat-
ment used. From our results, 40% of patients have
experienced a period of stable disease. The varia-
bility of natural history has signi® cant implications
for management in the individual patient. The
majority of patients will be successfully treated withStable phase in aggressive ® bromatosis 153
Table 4. Aggressive ® bromatosis treated by radiotherapy: response to treatment. x 5 no data,
n 5 number of patients in each category
Complete Partial Stable Progressive
Patients response response disease disease
Reference (n) (n) (n) (n) (n)
1 10 5 3 x 2, recurrence
7 4 4 x x x
9 24 15 3, controlled x x
10 8 6 2, disease persistence x x
11 13 9 4, residual disease x x
12 16 x 14, local control x 2
13 14 10 x x 4
14 21 15 2 4 x
15 13 7 1, local persistence x 5, recurrence
16 8 2 2 4 x
wide resection. Adjuvant radiotherapy can be
reserved for the minority with a signi® cant risk of
recurrence, particularly those with residual bulk dis-
ease or multiple previous recurrences. A proportion
of patients will be surgically incurable and options
for treatment include debulking surgery, radiother-
apy, hormone therapy or chemotherapy, if symp-
toms demand. Most options have potentially serious
adverse effects, most importantly induction of a
second malignancy. It is our opinion that a
signi® cant proportion of these patients may reach a
stable phase of their disease and hence not require
further treatment with agents that may have serious
long-term toxicity. The dif® culty is to identify these
patients. This study has not revealed any particular
features (other than multiple recurrences) which are
less likely to have a stable phase.
Conclusion
The natural history of aggressive ® bromatosis is
variable and can include a substantial period of
stable disease in a signi® cant proportion of patients.
Aggressive ® bromatosis rarely causes life-threaten-
ing complications, although it may be fatal.
22
Hence, we have adopted a non-aggressive approach
to management following attempted wide excision.
We initially observe unresectable or recurrent dis-
ease on this `stable phase’ principle. Debulking
surgery is frequently of value for palliation. We now
have a series of patients where the tumour has been
debulked to achieve a good cosmetic and functional
result. We tend to avoid the use of radiotherapy
even when resection is incomplete or if the margins
are positive, unless recurrence or further progression
could have a potentially serious outcome.
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